#United States #Parkinson's Disease #Jersey City #Mitsubishi Tanabe #ND0612

Mitsubishi Tanabe Pharma to Showcase ND0612 Research at AD/PD 2025

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has announced significant updates on their investigational drug ND0612, specifically designed for Parkinson's disease management. At the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) taking place from April 1-5 in Vienna, Austria, MTPA will present three informative poster sessions regarding ND0612. This investigational therapy utilizes a continuous subcutaneous infusion of liquid levodopa/carbidopa, providing 24-hour exposure for patients.

Key Highlights of the Presentation

Dr. Gustavo A. Suarez Zambrano, Vice President of Medical Affairs at MTPA, expressed enthusiasm regarding the opportunity to share crucial findings from the pivotal Phase 3 BouNDless trial. This trial is pivotal in understanding the efficacy and safety of ND0612, especially concerning motor fluctuations in Parkinson's disease patients.

The presentations will include:

1. Efficacy Evaluations: Subgroup analyses focusing on the drug's effectiveness among diverse patient profiles suffering from motor fluctuations, showcasing personalized treatment strategies.
2. Patient-Reported Outcomes: Insights into how ND0612 impacts the quality of life of those living with Parkinson's Disease, addressing critical needs currently unmet within this community.
3. Long-Term Outcomes: Highlights from the ongoing open-label extension phase, providing longitudinal data on ND0612's efficacy and safety.

The posters will be available for viewing in the exhibition hall on April 4-5 during conference hours from 10 a.m. to 5:30 p.m. CET.

Overview of ND0612

ND0612 aims to improve the management of motor fluctuations in Parkinson's disease through a combination therapy approach, emphasising the ease of a continuous delivery system. The drug has shed light on potential new avenues for patients who struggle with daily motor control and overall quality of life.

MTPA's ongoing commitment to addressing the challenges presented by Parkinson's Disease signifies a vital step towards enhancing treatment protocols for an underserved patient population. By harnessing both innovative drug mechanisms and rigorous research trials, MTPA hopes to forge ahead in their mission to support individuals and families affected by this condition.

Furthermore, MTPA operates as a vital subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), focusing on developing therapeutic solutions with high efficacy and patient satisfaction. MTPC is distinguished for its long-standing dedication to the pharmaceutical industry, emphasizing ethical practices since its founding in 1678.

Looking Ahead: The Future of Parkinson's Treatment

As MTPA gears up for the upcoming conference, the continued exploration of extensive treatment options for Parkinson's Disease brings hope to many who face the daily realities of this challenging condition. The presentations of ND0612 will not only showcase the advancements in medical therapies but serve as an encouragement to the medical community to prioritize research in areas that have significant unmet needs.

Attendees at the AD/PD 2025 will gain invaluable insights into the ND0612 project, prospectively leading to breakthroughs in treatment standards for those coping with Parkinson's and aiming for improvements in quality of life. For more information regarding the presentations and the work of MTPA, please visit their website.

With ongoing developments and patient-centric approaches, MTPA continues to highlight its dedication to revolutionizing Parkinson's disease management and enhancing patient outcomes effectively.